|Review of recently documented clinical neuroprotective and cellular treatment for spinal cord injury: an analysis of outcomes
|Hooshang Saberi1,2, Nazi Derakhshanrad1, Mir Saeed Yekaninejad1,3
|1Brain and Spinal Injuries Research Center,;
2Department of Neurosurgery, Imam Khomeini Hospital,;
3Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Abstract Emergence of new neuroprotective treatments for spinal cord injury (SCI) in recent clinical studies is a matter of great scientific and public interest. Effect size and complication rates are of particular concern. In this study, a search was performed in the PubMed, Scopus, and Scholar Google search engines using the keywords “spinal cord injury”, “cell transplantation” and “neuroprotective”. Clinical studies published in the English language were included. Using the study inclusion criteria, 45 clinically relevant studies were found in which neurologic changes was descriptively reported. Of these, 20 studies with American Spinal Injury Association scale, and sensory and motor reports were included for quantitative review. Overall, these papers show an increment in the number of studies reported since the turn of the century, and recent endeavors in the field have accelerated. To compare newer and older studies, considering sufficient numbers of studies in each group, the year 2010 was identified as the turning point. The mean ± standard deviation change in motor score after treatment was 8.67±3.48 in reports before 2010, and this increased to 8.95±2.78 after 2010. Similarly, the mean change in score for light touch was 9.57±3.63 before 2010 and increased to 10.58±3.06 after 2010. The mean change in score for pinprick sensation improved from 8.36±2.82 before 2010 to 8.39±2.69 after 2010. Our study indicates that cellular and neuroprotective therapies are becoming more popular, and the mean neurologic effect size in terms of light touch shows an increment, paving the pathway for clinical applications to be established in the near future.
Published: 26 December 2014
Hooshang Saberi, Keshavarz Blvd, Imam Khomeini Hospital Complex, Brain and Spinal Injury Research Center, Tehran 14185-61, Iran, Tel +98 21 6658 1560, Fax +98 21 6693 8885, Email firstname.lastname@example.org
| 1. Aidinoff E, Front L, Itzkovich M, et al.Expected spinal cord independence measure, third version, scores for various neurological levels after complete spinal cord lesions.Spinal Cord. 2011;49(8):893-896.
2. Harrop JS, Hashimoto R, Norvell D, et al.Evaluation of clinical experience using cell-based therapies in patients with spinal cord injury: a systematic review.J Neurosurg Spine. 2012;17(Suppl 1):230-246.
3. Kramer AS, Harvey AR, Plant GW, Hodgetts SI.Systematic review of induced pluripotent stem cell technology as a potential clinical therapy for spinal cord injury.Cell Transplant. 2013;22(4):571-617.
4. Firouzi M, Moshayedi P, Saberi H, et al.Transplantation of Schwann cells to subarachnoid space induces repair in contused rat spinal cord.Neurosci Lett. 2006;402(1-2):66-70.
5. Fehlings MG, Vawda R.Cellular treatments for spinal cord injury: the time is right for clinical trials.Neurotherapeutics. 2011;8(4):704-720.
6. Fawcett JW, Curt A, Steeves JD, et al.Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials.Spinal Cord. 2007;45(3):190-205.
7. Lammertse D, Tuszynski MH, Steeves JD, et al.Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design.Spinal Cord. 2007;45(3):232-242.
8. Steeves JD, Lammertse D, Curt A, et al.Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures.Spinal Cord. 2007;45(3):206-221.
9. Tuszynski MH, Steeves JD, Fawcett JW, et al.Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial inclusion/exclusion criteria and ethics.Spinal Cord. 2007;45(3):222-231.
10. Abdelaziz OS, Marie A, Abbas M, Ibrahim M, Gabr H.Feasibility, safety, and efficacy of directly transplanting autologous adult bone marrow stem cells in patients with chronic traumatic dorsal cord injury: a pilot clinical study.Neurosurg Q. 2010;20(3):216-226.
11. Adel N, Gabr H, Hamdy S, Afifi L, Mahmoud H.Stem cell therapy in chronic spinal cord injuries.Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2009;46(2):467-478.
12. Bhanot Y, Rao S, Ghosh D, Balaraju S, Radhika CR, Satish Kumar KV.Autologous mesenchymal stem cells in chronic spinal cord injury.Br J Neurosurg. 2011;25(4):516-522.
13. Callera F, de Melo CM. Magnetic resonance tracking of magnetically labeled autologous bone marrow CD34+ cells transplanted into the spinal cord via lumbar puncture technique in patients with chronic spinal cord injury: CD34+ cells’ migration into the injured site.Stem Cells Dev. 2007;16(3):461-466.
14. Chhabra HS, Lima C, Sachdeva S, et al. Autologous olfactory [corrected] mucosal transplant in chronic spinal cord injury: an Indian pilot study.Spinal Cord. 2009;47(12):887-895.
15. Kumar AA, Kumar SR, Narayanan R, Arul K, Baskaran M.Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: a phase I/II clinical safety and primary efficacy data.Exp Clin Transplant. 2009;7(4):241-248.
16. Pal R, Venkataramana NK, Bansal A, et al.Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: a pilot clinical study.Cytotherapy. 2009;11(7):897-911.
17. Mehta T, Feroz A, Thakkar U, Vanikar A, Shah V, Trivedi H.Subarachnoid placement of stem cells in neurological disorders.Transplant Proc. 2008;40(4):1145-1147.
18. Lima C, Escada P, Pratas-Vital J, et al.Olfactory mucosal autografts and rehabilitation for chronic traumatic spinal cord injury.Neurorehabil Neural Repair. 2009;24(1):10-22.
19. Cristante AF, Barros-Filho TE, Tatsui N, et al.Stem cells in the treatment of chronic spinal cord injury: evaluation of somatosensitive evoked potentials in 39 patients.Spinal Cord. 2009;47(10):733-738.
20. Mackay-Sim A, Feron F, Cochrane J, et al.Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3-year clinical trial.Brain. 2008;131(Pt 9):2376-2386.
21. Pitts LH, Ross A, Chase GA, Faden AI.Treatment with thyrotropin-releasing hormone (TRH) in patients with traumatic spinal cord injuries.J Neurotrauma. 1995;12(3):235-243.
22. Geisler FH, Dorsey FC, Coleman WP.Recovery of motor function after spinal-cord injury - a randomized, placebo-controlled trial with GM-1 ganglioside.N Engl J Med. 1991;324(26):1829-1838.
23. Guest J, Herrera LP, Qian T.Rapid recovery of segmental neurological function in a tetraplegic patient following transplantation of fetal olfactory bulb-derived cells.Spinal Cord. 2006;44(3):135-142.
24. Geffner LF, Santacruz P, Izurieta M, et al.Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies.Cell Transplant. 2008;17(12):1277-1293.
25. Ra JC, Shin IS, Kim SH, et al.Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans.Stem Cells Dev. 2011;20(8):1297-1308.
26. Kang KS, Kim SW, Oh YH, et al.A 37-year-old spinal cord-injured female patient, transplanted of multipotent stem cells from human UC blood, with improved sensory perception and mobility, both functionally and morphologically: a case study.Cytotherapy. 2005;7(4):368-373.
27. Yoon SH, Shim YS, Park YH, et al.Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: phase I/II clinical trial.Stem Cells. 2007;25(8):2066-2073.
28. Park HC, Shim YS, Ha Y, et al.Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor.Tissue Eng. 2005;11(5-6):913-922.
29. Park JH, Kim DY, Sung IY, et al.Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans.Neurosurgery. 2011;70(5):1238-1247.
30. Moviglia GA, Fernandez Vina R, Brizuela JA, et al.Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients.Cytotherapy. 2006;8(3):202-209.
31. Moviglia GA, Varela G, Brizuela JA, et al.Case report on the clinical results of a combined cellular therapy for chronic spinal cord injured patients.Spinal Cord. 2009;47(6):499-503.
32. Deda H, Inci MC, Kurekci AE, et al.Treatment of chronic spinal cord injured patients with autologous bone marrow-derived hematopoietic stem cell transplantation: 1-year follow-up.Cytotherapy. 2008;10(6):565-574.
33. Frolov AA, Bryukhovetskiy AS. Effects of haematopoietic autologous stem cell transplantation to the chronically injured human spinal cord evaluated by motor and somatosensory evoked potentials methods. Cell Transplant.2012;21 Suppl 1:S49-S55.
34. Rabinovich SS, Seledtsov VI, Poveschenko OV, et al.Transplantation treatment of spinal cord injury patients.Biomed Pharmacother. 2003;57(9):428-433.
35. Chernykh ER, Stupak VV, Muradov GM, et al.Application of autologous bone marrow stem cells in the therapy of spinal cord injury patients.Bull Exp Biol Med. 2007;143(4):543-547.
36. Seledtsova GV, Rabinovich SS, Belogorodtsev SN, Parlyuk OV, Seledtsov VI, Kozlov VA.Delayed results of transplantation of fetal neurogenic tissue in patients with consequences of spinal cord trauma.Bull Exp Biol Med. 2011;149(4):530-533.
37. Fehlings MG, Theodore N, Harrop J, et al.A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury.J Neurotrauma. 2011;28(5):787-796.
38. Falci S, Holtz A, Akesson E, et al.Obliteration of a posttraumatic spinal cord cyst with solid human embryonic spinal cord grafts: first clinical attempt.J Neurotrauma. 1997;14(11):875-884.
39. Huang H, Xi H, Chen L, Zhang F, Liu Y. Long-term outcome of olfactory ensheathing cell therapy for patients with complete chronic spinal cord injury. Cell Transplant.2012;21 Suppl 1:S23-S31.
40. Zhou XH, Ning GZ, Feng SQ, et al. Transplantation of autologous activated Schwann cells in the treatment of spinal cord injury: six cases, more than five years of follow-up. Cell Transplant.2012;21 Suppl 1:S39-S47.
41. Wu J, Sun T, Ye C, Yao J, Zhu B, He H. Clinical observation of fetal olfactory ensheathing glia transplantation (OEGT) in patients with complete chronic spinal cord injury. Cell Transplant.2012;21 Suppl 1:S33-S37.
42. Saberi H, Firouzi M, Habibi Z, et al.Safety of intramedullary Schwann cell transplantation for postrehabilitation spinal cord injuries: 2-year follow-up of 33 cases.J Neurosurg Spine. 2011;15(5):515-525.
43. Karamouzian S, Nematollahi-Mahani SN, Nakhaee N, Eskandary H.Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients.Clin Neurol Neurosurg. 2012;114(7):935-939.
44. Saito F, Nakatani T, Iwase M, et al.Spinal cord injury treatment with intrathecal autologous bone marrow stromal cell transplantation: the first clinical trial case report.J Trauma. 2008;64(1):53-59.
45. Saito F, Nakatani T, Iwase M, et al.Administration of cultured autologous bone marrow stromal cells into cerebrospinal fluid in spinal injury patients: a pilot study.Restor Neurol Neurosci. 2012;30(2):127-136.
46. Sakuma T, Yamazaki M, Okawa A, et al.Neuroprotective therapy using granulocyte colony-stimulating factor for patients with worsening symptoms of compression myelopathy, Part 1: a phase I and IIa clinical trial.Eur Spine J. 2012;21(3):482-489.
47. Sakuma T, Yamazaki M, Okawa A, et al.Neuroprotective therapy using granulocyte colony-stimulating factor for patients with worsening symptoms of thoracic myelopathy: a multicenter prospective controlled trial.Spine (Phila Pa 1976). 2012;37(17):1475-1478.
48. Takahashi H, Yamazaki M, Okawa A, et al.Neuroprotective therapy using granulocyte colony-stimulating factor for acute spinal cord injury: a phase I/IIa clinical trial.Eur Spine J. 2012;21(12):2580-2587.
49. Kishk NA, Gabr H, Hamdy S, et al.Case control series of intrathecal autologous bone marrow mesenchymal stem cell therapy for chronic spinal cord injury.Neurorehabil Neural Repair. 2010;24(8):702-708.
50. Cheng H, Liao KK, Liao SF, Chuang TY, Shih YH.Spinal cord repair with acidic fibroblast growth factor as a treatment for a patient with chronic paraplegia.Spine (Phila Pa 1976). 2004;29(14):E284-E288.
51. Knoller N, Auerbach G, Fulga V, et al.Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results.J Neurosurg Spine. 2005;3(3):173-181.
52. Sykova E, Homola A, Mazanec R, et al.Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury.Cell Transplant. 2006;15(8-9):675-687.
53. Hammadi AA, Marino A, Farhan S.Clinical response of 277 patients with spinal cord injury to stem cell therapy in Iraq.Int J Stem Cells. 2012;5(1):76-78.
54. Kato K, Yamazaki M, Okawa A, et al.Intravenous administration of granulocyte colony-stimulating factor for treating neuropathic pain associated with compression myelopathy: a phase I and IIa clinical trial.Eur Spine J. 2012;22(1):197-204.
55. Mackay-Sim A, St John JA.Olfactory ensheathing cells from the nose: clinical application in human spinal cord injuries.Exp Neurol. 2010;229(1):174-180.
56. Saberi H, Moshayedi P, Aghayan HR, et al.Treatment of chronic thoracic spinal cord injury patients with autologous Schwann cell transplantation: an interim report on safety considerations and possible outcomes.Neurosci Lett. 2008;443(1):46-50.
57. Rad ND, Saberi H, Yekaninejad MS, et al. Safety of granulocyte-colony stimulating factor (G-CSF) administration for post rehabilitated motor complete spinal cord injury patients: an open label, phase one study. Cell Transplant. August 29, 2013. [Epub ahead of print.]
58. Guest J, Harrop JS, Aarabi B, et al.Optimization of the decision-making process for the selection of therapeutics to undergo clinical testing for spinal cord injury in the North American Clinical Trials Network.J Neurosurg Spine. 2012;17(Suppl 1):94-101.